WO2016103390A1 - インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 - Google Patents
インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 Download PDFInfo
- Publication number
- WO2016103390A1 WO2016103390A1 PCT/JP2014/084285 JP2014084285W WO2016103390A1 WO 2016103390 A1 WO2016103390 A1 WO 2016103390A1 JP 2014084285 W JP2014084285 W JP 2014084285W WO 2016103390 A1 WO2016103390 A1 WO 2016103390A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin secretion
- hba1c
- value
- blood glucose
- fasting blood
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7282—Event detection, e.g. detecting unique waveforms indicative of a medical condition
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Definitions
- the present invention relates to an analyzer that analyzes an insulin secretory ability of an analysis subject, an analysis system including the analyzer, and an analysis method.
- Insulin is secreted from the pancreas and functions to regulate blood sugar levels. Diabetes is diagnosed by a diabetic type based on either the fasting blood glucose level, ad-hoc blood glucose level, or the blood glucose level 2 hours after the 75 g oral glucose tolerance test (OGTT) or hemoglobin A1c (HbA1c). The That is, if a subject is found to have a diabetes type more than once in tests performed on different days, diabetes is diagnosed. Diabetes mellitus progresses with almost no subjective symptoms and causes serious complications such as nephropathy, and countermeasures are important.
- OGTT oral glucose tolerance test
- HbA1c hemoglobin A1c
- insulin secretion ability has a great influence on the onset and progression of diabetes, and it is necessary to evaluate the insulin secretion ability of subjects in order to combat diabetes.
- an insulin secretion index calculated from a blood insulin concentration and a glucose tolerance test value is known as an evaluation index of insulin secretion ability.
- Patent Document 1 discloses a diabetes diagnosis support system that analyzes a patient's diabetes pathology based on patient test values and clinical findings and outputs diagnosis support information such as exercise therapy and diet therapy.
- diagnosis support information such as exercise therapy and diet therapy.
- fasting insulin level, blood glucose level, insulin level after glucose tolerance test, and the like are input values, and diagnosis support information about diabetes is output using a decrease in insulin secretion ability as one index.
- diagnosis support information about diabetes is output using a decrease in insulin secretion ability as one index.
- the insulin secretion ability is determined based on the input fasting insulin value and the insulin value after the glucose tolerance test.
- the insulin concentration for evaluating the insulin secretion ability as described above is usually measured using an insulin antibody by a chemiluminescence immunoassay (CLIA method).
- CLIA method chemiluminescence immunoassay
- the present invention provides an insulin secretion ability analyzing apparatus capable of evaluating insulin secretion ability by a simpler method as compared with the prior art, an insulin secretion ability analyzing system including the apparatus, and an insulin secretion ability analyzing method. It is an object.
- the present invention includes the following.
- An input unit that inputs at least a fasting blood glucose level and an HbA1c value
- an estimated HbA1c calculation unit that calculates an estimated HbA1c value from the input fasting blood glucose level and the HbA1c value
- an HbA1c value input at the input unit
- an insulin secretion ability evaluation value calculation unit that calculates an insulin secretion ability evaluation value based on the estimated HbA1c value calculated by the estimation HbA1c calculation part.
- the estimated HbA1c calculation unit is input using a relational expression between the fasting blood glucose level and the HbA1c value created based on the data set including the fasting blood glucose level and the HbA1c value for a plurality of subjects.
- the insulin secretion capacity analyzing apparatus according to (1), wherein an estimated HbA1c value is calculated from a fasting blood glucose level and an HbA1c value.
- the insulin secretion ability evaluation value calculation unit calculates the insulin secretion ability evaluation value based on a difference between the HbA1c value input by the input unit and the estimated HbA1c value calculated by the estimation HbA1c calculation unit.
- the insulin secretory analysis device according to (1) which is characterized in that
- the insulin secretory analysis device which is characterized in that
- a medical examination data storage unit storing a data set including fasting blood glucose levels and HbA1c values for a plurality of examinees, weight information input by the input unit, and the insulin secretion ability evaluation value calculation unit It further has a guidance target person selecting part for selecting a guidance target person related to diabetes from the data set stored in the medical examination data storage part from the calculated insulin secretion ability evaluation value (1 ) Insulin secretion capacity analyzer.
- the insulin secretion capacity analyzer according to any one of (1) to (7) above, and a terminal having a data set including at least a fasting blood glucose level and an HbA1c value related to the analysis target, and analyzed from the terminal
- An insulin secretion capacity analysis system wherein the data set related to a subject is input to the insulin secretion capacity analysis apparatus, and the insulin secretion capacity analysis apparatus analyzes the insulin secretion capacity related to the analysis target.
- (10) a step of inputting a fasting blood glucose level and an HbA1c value; a step of calculating an estimated HbA1c value from the input fasting blood glucose level and the HbA1c value; and the input HbA1c value and the calculated estimated HbA1c And a method of calculating an insulin secretion ability evaluation value based on the value.
- the insulin secretion capacity of the analysis subject is analyzed from the fasting blood glucose level and the HbA1c value of the analysis target. Therefore, the insulin secretory analysis apparatus according to the present invention can acquire information relating to insulin secretory at a much simpler and lower cost than in the past.
- the insulin secretion capacity of the analysis subject is analyzed by the insulin secretion capacity analysis device from the fasting blood glucose level and HbA1c value of the analysis target inputted from the terminal. Therefore, the insulin secretory analysis system according to the present invention can acquire information related to insulin secretory at a much simpler and lower cost than the conventional system.
- the insulin secretion capacity analyzing apparatus measures in advance fasting blood glucose level and HbA1c value for a blood sample collected from an analysis subject, and uses these fasting blood glucose level and HbA1c value in the analysis subject. It is a device for analyzing insulin secretion ability.
- the subject to be analyzed is not particularly limited and means the whole human. Examples of the analysis subject include health check-up examinees, diabetic patients (including types I and II), and those suspected of having diabetes.
- an insulin secretion capacity analyzing apparatus 101 to which the present invention is applied includes an input unit 102 for inputting at least a fasting blood glucose level and an HbA1c value, and a fasting time input by the input unit 102.
- an estimated HbA1c calculation unit 109 that calculates the estimated HbA1c value from the blood glucose level and the HbA1c value, and the estimated HbA1c value calculated by the estimated HbA1c calculation unit 109 and the HbA1c value input by the input unit 102
- an insulin secretion ability evaluation value calculation unit 110 for calculation.
- the insulin secretory analysis device 101 develops an output unit 103 that outputs the result of analyzing the insulin secretory ability, a CPU 104 that executes various information processing programs, an information processing program to be executed, and data used by the information processing program
- a memory 105 and a storage medium 106 storing information processing programs such as an estimated HbA1c calculation unit 109 and an insulin secretory capacity evaluation value calculation unit 110 are provided.
- the relational expression used by the estimated HbA1c calculation unit 109 and the evaluation expression used by the insulin secretion ability evaluation value calculation unit 110 are stored in the database 120. It may be configured as an insulin secretory analysis system acquired from However, the relational expression used by the estimated HbA1c calculation unit 109 and / or the evaluation expression used by the insulin secretion ability evaluation value calculation unit 110 is not limited to a form using the external database 120, and is stored in the storage medium 106, for example. Alternatively, it may be a form that is read from the storage medium 106 and used.
- the input unit 102 can be a human interface such as a mouse or a keyboard, and accepts an input to the insulin secretory analysis device 101.
- an input device that can input a fasting blood glucose level and an HbA1c value as a result of blood analysis of the analysis subject can be cited.
- the input unit 102 may be, for example, a network interface that can input information via a network with a terminal that stores the blood analysis result of the analysis target person, or is equipped with a measuring device that performs blood analysis of the analysis target person.
- An interface such as a USB for inputting information from the measuring instrument may be used.
- Examples of the output unit 103 include a display and a printer that output a calculation result by the insulin secretion capacity analyzing apparatus 101. Further, the output unit 103 may be an interface that outputs the insulin secretion ability evaluation value calculated by the insulin secretion ability evaluation value calculation unit 110 to an external terminal.
- the storage medium 106 is a storage device that stores various programs that realize the insulin secretion ability analysis processing by the insulin secretion ability analysis terminal 101, the execution results of the insulin secretion ability analysis processing, and the like. Drive, non-volatile memory, etc.).
- the CPU 104 is an arithmetic device that executes a program loaded in the memory 105, and is a CPU, a GPU, or the like, for example.
- the CPU 104 executes the processes and operations described below.
- the insulin secretion capacity analyzing apparatus 101 is a computer system configured on a single computer or a plurality of logically or physically configured computers, and operates on separate threads on the same computer. Alternatively, it may operate on a virtual machine constructed on a plurality of physical computer resources.
- the program executed by the CPU 104 may be provided to each server via a removable medium (CD-ROM, flash memory, etc.) or a network, and may be stored in a nonvolatile storage device that is a non-temporary storage medium.
- the insulin secretion capacity analyzing apparatus 101 may include an interface for reading a removable medium.
- the relational expression used by the estimated HbA1c calculation unit 109 is, as will be described in detail later, fasting blood glucose included in the medical examination data of a plurality of examinees This means a relational expression for statistically processing the relationship between the value and the HbA1c value and calculating the estimated HbA1c value from the fasting blood glucose level.
- the evaluation formula for calculating the insulin secretion ability evaluation value means an expression for calculating an evaluation value for evaluating the insulin secretion ability from the actual HbA1c value of the analysis subject and the estimated HbA1c value.
- the medical examination data of the plurality of examinees used when creating the relational expression used by the estimated HbA1c calculation unit 109 may include the medical examination data of the analysis target person.
- the insulin secretion capacity analyzing apparatus 101 shown in FIG. 1 has a configuration in which these relational expressions and / or evaluation expressions are acquired from the external database 120.
- the insulin secretion capacity analyzing apparatus according to the present invention is not limited to such a configuration, and creates a relational expression for calculating an estimated HbA1c value and creates an evaluation expression for evaluating insulin secretion capacity. Also good.
- the insulin secretory analysis apparatus that creates these relational expressions and evaluation formulas stores a relational expression creation unit 107 and an insulin secretion ability evaluation formula creation unit 108 as shown in FIG. 2, for example. It is stored in the medium 106.
- the relational expression creating unit 107 acquires the fasting blood glucose level and the HbA1c value included in the medical examination data for a plurality of persons input to the input unit 102, and statistically processes the relationship between the HbA1c value and the fasting blood glucose level. Then, a relational expression for calculating the estimated HbA1c from the fasting blood glucose level is created.
- the insulin secretory evaluation formula creating unit 108 creates an evaluation formula for evaluating the insulin secretory ability from the estimated HbA1c value calculated by the relational formula creating unit 107 and the HbA1c value input by the input unit 102.
- the estimated HbA1c calculation unit 109 acquires the fasting blood glucose level of the analysis target inputted to the input unit 102 and the relational expression created by the relational expression creation unit 107. And the estimated HbA1c value is calculated.
- the insulin secretion capacity evaluation value calculation unit 110 includes the HbA1c value of the analysis subject input to the input unit 102 and the estimated HbA1c value calculated by the estimated HbA1c calculation unit 109. Is substituted into the evaluation formula created by the insulin secretion capability evaluation formula creation unit 108, and the insulin secretion capability evaluation value is calculated.
- the insulin secretion capacity analyzing apparatus 101 shown in FIG. 2 stores the instruction target person selecting unit 111 in the storage medium 106, and when the information about the weight change of the analysis target person is input by the input unit 102 Can determine whether the subject to be analyzed is in the previous stage of diabetes based on the information on the insulin secretion ability evaluation value and the weight change calculated by the insulin secretion ability evaluation value calculation unit 110, and can guide the prevention of diabetes. Can be selected as a target person.
- the relational expression creating unit 107 and the insulin secretory capacity evaluation formula creating part 108 create a relational expression and an evaluation formula, respectively, based on the medical examination data of a plurality of persons stored in the database 120.
- the database 120 includes a medical examination data storage unit 121 that stores medical examination data of a plurality of persons.
- the database 120 includes a relational expression storage unit 122 that stores the relational expression created by the relational expression creation unit 170, an evaluation formula storage unit 123 that stores an evaluation formula created by the insulin secretion capacity evaluation formula creation unit 108, and an instruction target.
- storage part 124 which stored the information regarding the guidance subject selected by the person selection part 111 may be sufficient.
- the configuration of the medical examination data stored in the medical examination data storage unit 121 is shown in FIG.
- the medical examination data 200 includes medical examination data for a plurality of years of a plurality of medical examination recipients.
- the medical examination data 200 includes a medical examiner ID 201, a medical examination reception date 202, a fasting blood glucose level 203, an HbA1c value 204, a diabetes determination 205, and the like assigned to each individual who has undergone the medical examination.
- an identifier of a medical checkup person who has received a medical checkup or a medical checkup is registered.
- information indicating the date of medical checkup and medical checkup is registered.
- the fasting blood glucose level 203 and the HbA1c value 204 are the fasting blood glucose level and the HbA1c value of the health checkup examinee identified by the health checker ID 201 after being examined by a health checkup or a medical checkup.
- the fasting blood glucose level 203 is a fasting blood glucose level and is a numerical value measured by a conventional method and having a unit of mg / dl or mol / l.
- the HbA1c value 204 is a value indicating an average of blood glucose levels over 2 to 3 months, and is a numerical value having a unit of% (JDS value),% (NGSP value), mmol / mol or the like.
- Diabetes determination 205 is a value indicating whether or not diabetes is being treated. In this example, “1” is present and “0” is absent.
- the medical examination data may include other disease determinations, family histories, past histories, weights, and the like.
- FIG. 4 is an example of a flowchart in which the relational expression creating unit 107 creates a relational expression between fasting blood glucose and HbA1c from the medical examination data in FIG.
- a medical examination data input step 301 is performed.
- the relational expression creating unit 107 acquires the medical examination data 200 stored in the medical examination data storage unit 121.
- the relational expression creation unit 107 extracts relational expression creation data from the medical examination data 200 acquired in the medical examination data input step 301.
- the diabetes determination 205 extracts analysis medical examination data indicating that there is no “0” during the treatment of diabetes. Since fasting blood glucose and HbA1c are affected by drugs, analysis medical examination data excluding these effects can be extracted.
- the relational expression creation unit 107 creates a relational expression using the medical examination data for analysis extracted in the analysis data extraction step 302. Specifically, the relationship between the fasting blood glucose level 203 and the HbA1c value 204 included in the analysis medical examination data extracted in the analysis data extraction step 302 is statistically processed, and the estimated HbA1c value is calculated from the fasting blood glucose level.
- Create a relational expression Specifically, a relational expression can be created by performing regression analysis using the HbA1c value 204 as an objective variable and the fasting blood glucose level 203 as an explanatory variable.
- the relational expression storage unit 122 can store the created relational expression.
- the relational expression created by the relational expression creating unit 107 can calculate the estimated HbA1c value from the fasting blood glucose level of the analysis subject.
- the relational expression data 400 shown in FIG. 5 stores a relational expression 403 for each set of a unit 401 of HbA1c value and a unit 402 of fasting blood glucose level.
- A1 to A3 and B1 to 3 are coefficients calculated by the above-described regression analysis for each set of the unit 401 of the HbA1c value and the unit 402 of the fasting blood glucose level.
- the insulin secretory analyzing apparatus 101 can output the relational expression created by the relational expression creation unit 107 as described above as a screen 500 in the output unit 103 as shown in FIG.
- the output unit 103 includes relational expressions 511, 521, and 531 created for each combination of the unit 401 for the HbA1c value and the unit 402 for the fasting blood glucose level, and the analysis data 501 used for creating the relational expression.
- relational lines 510, 520, and 530 can be displayed.
- FIG. 7 shows that the insulin secretion capacity evaluation formula creating unit 108 has the medical examination data including the fasting blood glucose level and the HbA1c value shown in FIG. 3 and the estimated HbA1c value obtained from the relational formula created by the relational formula creating unit 107.
- 3 is an example of a flowchart for creating an evaluation formula for evaluating the insulin secretory ability of an analysis subject.
- the insulin secretion capacity evaluation formula creating unit 108 acquires the medical examination data 200 stored in the medical examination data storage unit 121.
- the insulin secretion capacity evaluation formula creating unit 108 extracts data for creating an evaluation formula from the medical examination data 200 acquired in the medical examination data input step 601. Specifically, for each medical examiner ID 201, the medical examination data 202 is extracted with reference to the medical examination reception date 202 for different years. For example, medical examination data having different fiscal years such as fiscal 2004 and fiscal 2009 is extracted for each medical examiner ID 201. Next, referring to the diabetes determination 205 of the medical examination data of the older year (in this example, the 2004 fiscal year), the medical examination data of the medical examiner ID 201 having “1” being treated for diabetes is excluded, and the evaluation formula Extract creation data. Thus, it is possible to analyze whether or not a person who was not treating diabetes in the first year (fiscal 2004 in this example) was subsequently treated for diabetes (diabetes treatment probability).
- the insulin secretion capacity evaluation formula creating unit 108 obtains a relational expression in which the units of the fasting blood glucose level and the HbA1c value match from the relational expression data in FIG. . Then, for all medical examiner IDs 201 included in the evaluation formula creation data, the fasting blood glucose level included in the evaluation formula creation data extracted in the analysis data extraction step 602 is substituted into the relational expression, and the estimated HbA1c value is calculated. It calculates for every medical examiner ID201. Further, for each medical examiner ID 201, the difference between HbA1c and estimated HbA1c is calculated by subtracting the estimated HbA1c value calculated above from the HbA1c value included in the evaluation formula creation data.
- the insulin secretion capacity evaluation formula creating unit 108 calculates the correction value from the relationship between the difference value calculated in the difference calculation step 603 between the HbA1c value and the estimated HbA1c value and the presence or absence of diabetes treatment. Is determined by ROC analysis (Receiver Operating Characteristic analysis). Specifically, the difference between the HbA1c value and the estimated HbA1c of the older one (fiscal 2004 in this example) of the health examination data for two years with different years included in the evaluation formula creation data, and the year An ROC curve is created from the relationship of the diabetes treatment probability of the newer medical examination data (in this example, fiscal 2009), and the value with the highest sensitivity + specificity is determined as the correction value.
- ROC analysis Receiveiver Operating Characteristic analysis
- the insulin secretion capacity evaluation formula creation unit 108 uses the difference value between the HbA1c and estimated HbA1c calculated in the difference calculation step 603 between the HbA1c value and the estimated HbA1c, and the correction value determination step 604.
- An evaluation formula is created from the determined correction value.
- the evaluation formula is a formula obtained by subtracting the correction value from the difference between HbA1c and estimated HbA1c.
- the created evaluation formula can be stored in the evaluation formula storage unit 123.
- the evaluation formula data shown in FIG. 8 can calculate an evaluation value from the HbA1c value and the estimated HbA1c value of the analysis subject.
- the evaluation formula data 700 shown in FIG. 8 stores an evaluation formula 703 for each set of a unit 701 of HbA1c value and a unit 702 of fasting blood glucose level.
- the evaluation formula 703 is a relational expression created by the insulin secretion ability evaluation formula creation unit 108 described above, and is described in the form of [HbA1c value] ⁇ [estimated HbA1c value] ⁇ Th1 to 3 as an example.
- Th1 to 3 are correction values calculated by the ROC analysis described above for each set of the unit 701 of the HbA1c value and the unit 702 of the fasting blood glucose level.
- the insulin secretion capacity analyzing apparatus 101 that has calculated the relational expression and the evaluation expression can calculate the evaluation value of the insulin secretion capacity of the analysis subject according to the flowchart shown in FIG. 9, for example.
- a fasting blood glucose / HbA1c input step 801 is performed.
- the estimated HbA1c calculation unit 109 causes the input unit 102 to input at least the fasting blood glucose level and the HbA1c value for the subject to be analyzed. At this time, information relating to the weight increase / decrease of the analysis subject may be input.
- the estimated HbA1c calculation unit 109 first acquires relational expression data stored in the relational expression storage unit 122.
- the estimated HbA1c calculation unit 109 has a relationship in which both the fasting blood glucose unit and the HbA1c value unit of the analysis subject input in the fasting blood glucose / HbA1c input step 801 are matched from the relational expression data. Select an expression.
- the estimated HbA1c value regarding an analysis object person is calculated by substituting the input fasting blood glucose level with respect to the selected relational expression.
- the insulin secretion ability evaluation value calculation unit 110 first obtains evaluation expression data stored in the evaluation expression storage unit 123. Next, the insulin secretion ability evaluation value calculation unit 110 selects, from the evaluation formula data, an evaluation formula 703 in which both the unit of the fasting blood glucose level of the analysis target and the unit of HbA1c match. Then, the estimated HbA1c value calculated by the estimated HbA1c calculating unit 109 and the HbA1c value input in the fasting blood glucose / HbA1c input step 801 are respectively substituted into the selected evaluation formula to calculate an evaluation value related to the insulin secretion ability. .
- the evaluation formula calculated as described above it can be determined that the insulin secretion ability is low when the calculated evaluation value is positive, and the insulin secretion ability is high when the calculated value is negative.
- the evaluation value related to the insulin secretion ability calculated by the insulin secretion ability evaluation value calculation unit 110 is compared with the information on the insulin secretion ability (the insulin secretion ability is high or Information such as low).
- information on the insulin secretion ability can be output to the output unit 103 for the analysis target person.
- the insulin secretion capacity calculating process is completed.
- the insulin secretory ability can be easily evaluated from the fasting blood glucose level and HbA1c level which are examined by a general medical examination or a medical checkup. That is, according to the insulin secretion capacity analyzing apparatus 101 according to the present invention, it is not necessary to measure the insulin concentration which is not examined by a general health check or a medical checkup, and it is divided into two times after fasting and after a glucose tolerance test. There is no need to collect blood and analyze each blood sample. Thus, according to the insulin secretion capacity analyzing apparatus 101 according to the present invention, the insulin secretion capacity can be determined very easily.
- the insulin secretion capacity analyzing apparatus 101 when information (weight information) related to a change in body weight of an analysis subject is input through the input unit 102, the weight information and the insulin secretion capacity evaluation value. Based on the above, it is preferable to include a guidance necessity determination unit that determines whether or not the analysis subject needs guidance regarding diabetes. In the instruction necessity determination unit, when the insulin secretory ability of the analysis target person is reduced and the weight information indicates an increase in weight, it is determined that the analysis target person is instructed to prevent diabetes.
- FIG. 10 shows a result 900 obtained by evaluating the insulin secretion ability evaluation value calculated by the insulin secretion ability analyzing apparatus 101 according to the present invention described above using a conventional insulin secretion index.
- FIG. 10 shows the result of calculating the insulin secretion index evaluation value 901 into two groups, positive and negative, and calculating the mean ⁇ standard deviation 903 of the insulin secretion index for each correction value Th1902.
- a result of calculating a significance probability 904 by performing a T test on the difference between the average values of the two groups is also shown.
- FIG. 10 shows an evaluation result using data of 24 people, and a group having a positive insulin secretion ability evaluation value has a lower average value of the insulin secretion index.
- the insulin secretion ability evaluation value calculated by the insulin secretion ability analyzer 101 according to the present invention is the subject of analysis with the same accuracy as the system for evaluating insulin secretion ability using the conventional insulin secretion index. It was shown that insulin secretion ability can be evaluated.
- FIG. 11 shows a result 1000 obtained by evaluating the insulin secretion ability evaluation value calculated by the insulin secretion ability analyzer 101 according to the present invention described above based on the presence or absence of diabetes treatment after 5 years.
- the insulin secretion ability evaluation value 1001 is divided into two groups, positive and negative, and the correction value Th11002 is divided into the multivariate adjustment odds ratio 1003 of diabetes treatment (diabetes onset) and the lower limit of its 95% confidence interval (95% CI)
- the result of calculating 1004 and the upper limit 1005 is shown.
- the multivariate adjusted odds ratio shows the odds ratio of the positive group when the insulin secretion ability evaluation value 1001 is set to 1 in the negative group, and is another covariate related to the onset of diabetes, gender, age, Values adjusted for BMI, fasting blood glucose, and diabetic family history.
- the multivariate adjusted odds ratio 1003 and the 95% CI lower limit 1004 in FIG. 11 the positive group of the insulin secretion ability evaluation value 1001 has a 4.25 times or more probability of diabetes treatment after 5 years compared to the negative group, Since the 95% CI lower limit exceeds 1, the result is significantly higher. From the results shown in FIG. 11, it is clear that the insulin secretion ability evaluation value calculated by the insulin secretion ability analyzer 101 according to the present invention can be used to easily evaluate the insulin secretion ability and evaluate the risk of future diabetes. It became.
- the instruction target person selecting unit 111 can further execute the instruction target person selecting process.
- a guidance target person selecting process can be executed according to a flowchart as shown in FIG.
- an example of the subject selection screen used for the guidance subject selection process is shown in FIG.
- a guidance number input step 1100 is performed.
- the number of instructions is input to the instruction number input field 1201 of the target person selection screen in FIG.
- the guidance number input field 1201, the scatter diagram 1202 of the candidate candidate's HbA1c value and the estimated HbA1c value, the graph 1203 showing the insulin secretion ability evaluation formula, the determination of the level of insulin secretion ability Reference 1204 is shown.
- the ID 1210, HbA1c401, estimated HbA1c1212, insulin secretion ability evaluation value 1213, evaluation result 1214 of the insulin secretion ability level, weight change 1215, and instruction priority 1216 of each candidate candidate are displayed. Displayed in tabular form.
- a selection result output button 1220 for outputting a selection result of the guidance target person is displayed on the target person selection screen 1200 shown in FIG.
- the instructor selection unit 111 sets the insulin secretion ability evaluation value calculated by the insulin secretion ability evaluation value calculation unit 110 for a plurality of persons, the insulin secretion ability evaluation value 1213. Enter in the field.
- the inputted insulin secretion ability evaluation value evaluates the level of insulin secretion ability, and is displayed in a tabular form together with HbA1c401 and estimated HbA1c1212 for each ID 1210 as shown in FIG.
- the guidance subject selecting unit 111 causes the input unit 102 to input the amount of weight change for a plurality of people.
- the input weight change amount is displayed in a table format for each ID 1210 as shown in FIG.
- the guidance subject selection unit 111 determines the insulin secretion ability evaluation value input in the insulin secretion ability evaluation value input step 1101 and the weight change amount input in the weight change input step 1102. Based on the above, the number of persons to be instructed is selected by the number of instructors input in the instructor number input step 1100. Specifically, the guidance priority of a person with a high insulin secretion ability evaluation value and a large amount of weight change is increased, and only the guidance number of persons is selected as a guidance subject. In FIG. 13, a person with a small instruction priority 1216 is shown as a person with a high insulin secretion ability evaluation value and a large amount of weight change. When the guidance target person is determined, the selection result output button 1220 in FIG. 13 is pressed to output the target person list.
- the instruction target person selecting unit 111 can complete the instruction target person selecting process.
- FIG. 14 shows the result of evaluating the presence or absence of diabetes treatment after 5 years when the insulin secretion ability evaluation value calculated by the insulin secretion ability analyzer 101 according to the present invention described above and the change in body weight are combined. It was.
- the insulin secretion ability evaluation value 1301 is divided into two groups, positive and negative, and the multivariate adjustment odds ratio 1304 for diabetes treatment (diabetes onset) according to the correction value Th1 1302 and the body weight change 1303 and its 95% confidence interval (95%
- the results of calculating the lower limit 1305 and the upper limit 1306 of CI) are shown.
- the multivariate adjusted odds ratio indicates the odds ratio of each group when the insulin secretion ability evaluation value 1301 is negative and the weight change 1303 is 1 in the group of ⁇ 1 kg. Covariate values adjusted for gender, age, BMI, fasting blood glucose, and family history of diabetes. From the multivariate adjusted odds ratio 1304 and the 95% CI lower limit 1305 in FIG. 14, the group whose insulin secretion ability evaluation value 1301 is positive and increased by 1 kg or more has a probability of diabetes treatment of 10.5 times or more after 5 years, Since the 95% CI lower limit exceeds 1, the result is significantly higher.
- the insulin secretion capacity analyzing apparatus 101 combines the information about the change in body weight with the insulin secretion capacity evaluation value calculated by the insulin secretion capacity evaluation value calculation unit 110, thereby further risk of diabetes in the future. Can be obtained.
- the insulin secretion capacity analyzing apparatus 101 according to the present invention appropriately combines the insulin secretion capacity evaluation value calculated by the insulin secretion capacity evaluation value calculation unit 110 with the information on the change in body weight, so that the person to be instructed for diabetes can be appropriately treated. Can be selected.
- the insulin secretion capacity evaluation formula creating unit 108 calculates a correction value from the relationship between the difference between the HbA1c value and the estimated HbA1c value and the presence or absence of diabetes treatment, and the evaluation formula of FIG.
- the evaluation formula is not limited to this method, and the evaluation formula can be created by other methods.
- the insulin secretory analysis apparatus 101 performs ROC analysis on the relationship between the difference between the HbA1c value and the estimated HbA1c value and the presence or absence of diabetes treatment for each estimated HbA1c value, and calculates and evaluates a correction value for each estimated HbA1c value.
- An expression may be created. That is, in this example, as shown in FIG.
- the created evaluation formula stores an evaluation formula 1404 for each estimated HbA1c value 1403 for each set of unit 701 for HbA1c value and unit 702 for fasting blood glucose level.
- EH11 and EH12 are correction values calculated for sets in which the unit 701 of the HbA1c value is “% (JDS)” and the unit 702 of the fasting blood glucose level is “mg / dl”. I mean.
- the insulin secretion ability can be evaluated with higher accuracy by creating an evaluation formula using correction values that differ depending on the estimated HbA1c value.
- the risk of future diabetes can be evaluated more accurately by using an evaluation formula using a correction value that differs depending on the estimated HbA1c value.
- the target person is selected without considering the weight change.
- the person to be instructed may be selected using other information and the insulin secretory evaluation value instead of the weight change or instead of the weight change.
- the terminal may be a server computer storing a result of a health check, or may be a home blood glucose measuring device, for example.
- an insulin secretory analysis system using a home-use blood glucose measuring device or the like, it is possible to easily measure the HbA1c value and the fasting blood glucose level with the device and grasp its own insulin secretory ability. . And by utilizing such an insulin secretion ability analysis system, it can be utilized for daily insulin treatment based on the insulin secretion ability evaluation value.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Data Mining & Analysis (AREA)
- Optics & Photonics (AREA)
- Primary Health Care (AREA)
- Databases & Information Systems (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Food Science & Technology (AREA)
- Signal Processing (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Diabetes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
102 入力部
103 出力部
104 CPU
105 メモリ
106 記憶媒体
107 関係式作成部
108 インスリン分泌能評価式作成部
109 推定HbA1c算出部
110 インスリン分泌能評価値算出部
111 指導対象者選定部
120 データベース
121 健診情報記録部
122 関係式記憶部
123 評価式記憶部
124 指導対象者記憶部
Claims (10)
- 少なくとも空腹時血糖値とHbA1c値とを入力する入力部と、
入力した空腹時血糖値とHbA1c値とから推定HbA1c値を算出する推定HbA1c算出部と、
前記入力部で入力したHbA1c値と前記推定HbA1c算出部で算出した推定HbA1c値とに基づいてインスリン分泌能評価値を算出するインスリン分泌能評価値算出部と
を備えるインスリン分泌能分析装置。 - 前記推定HbA1c算出部は、複数の被検査者に関する空腹時血糖値とHbA1c値とを含むデータセットに基づいて作成した空腹時血糖値とHbA1c値との関係式を用いて、入力した空腹時血糖値とHbA1c値とから推定HbA1c値を算出することを特徴とする請求項1記載のインスリン分泌能分析装置。
- 前記関係式は、前記HbA1c値を目的変数とし、前記空腹時血糖値を説明変数として回帰分析することで作成されることを特徴とする請求項2記載のインスリン分泌能分析装置。
- 前記インスリン分泌能評価値算出部は、前記入力部で入力したHbA1c値と前記推定HbA1c算出部で算出した推定HbA1c値との差分に基づいて前記インスリン分泌能評価値を算出することを特徴とする請求項1記載のインスリン分泌能分析装置。
- 前記インスリン分泌能評価値算出部で算出したインスリン分泌能評価値と基準値とを比較してインスリン分泌能に関する情報を出力する出力部を更に有することを特徴とする請求項1記載のインスリン分泌能分析装置。
- 前記入力部で入力した体重情報と、前記インスリン分泌能評価値算出部で算出したインスリン分泌能評価値とから、糖尿病に関する指導要否を判定する指導要否判定部を更に有することを特徴とする請求項1記載のインスリン分泌能分析装置。
- 複数の被検査者に関する空腹時血糖値とHbA1c値とを含むデータセットを格納した健診データ記憶部と、前記入力部で入力した体重情報と、前記インスリン分泌能評価値算出部で算出したインスリン分泌能評価値とから、前記健診データ記憶部に格納されたデータセットのなかから、糖尿病に関する指導対象者を選定する指導対象者選定部とを更に有することを特徴とする請求項1記載のインスリン分泌能分析装置。
- 請求項1乃至7いずれか一項記載のインスリン分泌能分析装置と、
分析対象者に関する少なくとも空腹時血糖値とHbA1c値とを含むデータセットを有する端末と、
を備え、前記端末から分析対象者に関する前記データセットを前記インスリン分泌能分析装置に入力し、前記インスリン分泌能分析装置にて分析対象者に関するインスリン分泌能を分析することを特徴とするインスリン分泌能分析システム。 - 前記端末は、分析対象者に関する空腹時血糖値を測定する及び/又はHbA1c値を測定する測定器であることを特徴とする請求項8記載のインスリン分泌能分析システム。
- 空腹時血糖値とHbA1c値とを入力する工程と、
入力した前記空腹時血糖値と前記HbA1c値とから推定HbA1c値を算出する工程と、
入力した前記HbA1c値と算出した前記推定HbA1c値とに基づいてインスリン分泌能評価値を算出する工程と
を備えるインスリン分泌能分析方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2014/084285 WO2016103390A1 (ja) | 2014-12-25 | 2014-12-25 | インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 |
CN201480083933.XA CN107003315B (zh) | 2014-12-25 | 2014-12-25 | 胰岛素分泌能力分析装置、具备该装置的胰岛素分泌能力分析系统以及胰岛素分泌能力分析方法 |
US15/517,642 US20170316176A1 (en) | 2014-12-25 | 2014-12-25 | Device for analyzing insulin secretion ability, system for analyzing insulin secretion ability provided with same, and method for analyzing insulin secretion ability |
JP2016565750A JP6401297B2 (ja) | 2014-12-25 | 2014-12-25 | インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2014/084285 WO2016103390A1 (ja) | 2014-12-25 | 2014-12-25 | インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016103390A1 true WO2016103390A1 (ja) | 2016-06-30 |
Family
ID=56149486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/084285 WO2016103390A1 (ja) | 2014-12-25 | 2014-12-25 | インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20170316176A1 (ja) |
JP (1) | JP6401297B2 (ja) |
CN (1) | CN107003315B (ja) |
WO (1) | WO2016103390A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021025791A (ja) * | 2019-07-31 | 2021-02-22 | アークレイ株式会社 | 推定方法及び平均血糖値推定システム |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10925547B2 (en) * | 2017-01-16 | 2021-02-23 | Bionime Corporation | System for monitoring physiological condition |
KR102492194B1 (ko) * | 2020-06-11 | 2023-01-27 | 고려대학교 산학협력단 | 췌장 인슐린 분비능 평가 지표 제공 방법 및 장치 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003083133A1 (fr) * | 2002-03-29 | 2003-10-09 | Asahi Kasei Pharma Corporation | Methode de detection d'une intolerance legere au glucose ou d'une hyposecretion d'insuline |
JP2005535885A (ja) * | 2002-08-13 | 2005-11-24 | ユニヴァースティ オブ ヴァージニア パテント ファウンデイション | 糖尿病自己管理を推進するための自己モニタリング血糖(smbg)データを処理するための方法、システムおよびコンピュータ・プログラム・プロダクト |
JP2006304833A (ja) * | 2005-04-26 | 2006-11-09 | Sysmex Corp | 診断支援システム及びコンピュータプログラム |
JP2007304088A (ja) * | 2006-03-31 | 2007-11-22 | Lifescan Inc | 糖尿病管理方法及びシステム |
JP2013092537A (ja) * | 2007-03-30 | 2013-05-16 | Tanita Corp | 血糖状態推定方法及び装置 |
JP2014095715A (ja) * | 2006-09-22 | 2014-05-22 | Arkray Inc | 血液分析装置 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI112545B (fi) * | 1997-05-30 | 2003-12-15 | Nokia Corp | Menetelmä ja järjestelmä potilaan veren glykosyloidun hemoglobiinikomponentin tason ennustamiseksi |
EP1253942A4 (en) * | 2000-02-01 | 2004-06-16 | Tanox Inc | CD40-BINDING AND APC-ACTIVATING MOLECULES |
CN101079082A (zh) * | 2002-08-13 | 2007-11-28 | 弗吉尼亚大学专利基金会 | 用于处理自我监测血糖(smbg)数据从而提高糖尿病患者自我管理的方法、系统和计算机程序产品 |
CN101275953A (zh) * | 2007-03-30 | 2008-10-01 | 株式会社百利达 | 血糖状态推定方法以及装置 |
JP5501963B2 (ja) * | 2007-07-09 | 2014-05-28 | ユニバーシティ オブ バージニア パテント ファウンデーション | 自己監視データから糖尿病におけるインシュリン感度、インシュリン/炭水化物比率、及びインシュリン補正機能を評価するためのシステム及びコンピュータプログラム製品 |
CA2690541A1 (en) * | 2007-07-17 | 2009-01-29 | Metabolon, Inc. | Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same |
KR20110058789A (ko) * | 2008-08-08 | 2011-06-01 | 유니버시티 오브 조지아 리서치 파운데이션 인코퍼레이티드 | 체액으로 분비될 수 있는 단백질을 예측하기 위한 방법 및 시스템 |
WO2011084208A1 (en) * | 2009-12-21 | 2011-07-14 | Stc.Unm | System and methods for estimating hba1c, treatment response, and hypoglycemia risk using self-monitoring of blood glucose data |
US20130095121A1 (en) * | 2010-06-25 | 2013-04-18 | Aoife Brennan | Methods of treating patients with immune-related diseases |
JP5900044B2 (ja) * | 2012-03-12 | 2016-04-06 | オムロンヘルスケア株式会社 | 糖尿病治療支援装置、糖尿病治療支援方法、糖尿病治療支援プログラム |
US20130316375A1 (en) * | 2012-05-24 | 2013-11-28 | Orban Biotech Llc | Diabetes biomarkers |
WO2013188605A2 (en) * | 2012-06-15 | 2013-12-19 | Nuclea Biotechnologies, Inc. | Predictive markers for cancer and metabolic syndrome |
US20140324460A1 (en) * | 2012-09-26 | 2014-10-30 | Health Diagnostic Laboratory, Inc. | Method for determining and managing total cardiodiabetes risk |
-
2014
- 2014-12-25 JP JP2016565750A patent/JP6401297B2/ja active Active
- 2014-12-25 CN CN201480083933.XA patent/CN107003315B/zh active Active
- 2014-12-25 US US15/517,642 patent/US20170316176A1/en not_active Abandoned
- 2014-12-25 WO PCT/JP2014/084285 patent/WO2016103390A1/ja active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003083133A1 (fr) * | 2002-03-29 | 2003-10-09 | Asahi Kasei Pharma Corporation | Methode de detection d'une intolerance legere au glucose ou d'une hyposecretion d'insuline |
JP2005535885A (ja) * | 2002-08-13 | 2005-11-24 | ユニヴァースティ オブ ヴァージニア パテント ファウンデイション | 糖尿病自己管理を推進するための自己モニタリング血糖(smbg)データを処理するための方法、システムおよびコンピュータ・プログラム・プロダクト |
JP2006304833A (ja) * | 2005-04-26 | 2006-11-09 | Sysmex Corp | 診断支援システム及びコンピュータプログラム |
JP2007304088A (ja) * | 2006-03-31 | 2007-11-22 | Lifescan Inc | 糖尿病管理方法及びシステム |
JP2014095715A (ja) * | 2006-09-22 | 2014-05-22 | Arkray Inc | 血液分析装置 |
JP2013092537A (ja) * | 2007-03-30 | 2013-05-16 | Tanita Corp | 血糖状態推定方法及び装置 |
Non-Patent Citations (2)
Title |
---|
HIROSHI SAITO ET AL.: "2-gata Tonyobyo Kanja no Glycoalbumin (GA)/HbA1C-hi wa Naiinsei Insulin Bunpitsuno ni Eikyo o Ukeru", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 50, no. Supplement 1, 25 April 2007 (2007-04-25), pages 86 * |
YUZURU KISHITANI: "Clinical Laboratory Examination of Diabetic Patients in Conjunction with Metabolic Syndrome", THE JAPANESE JOURNAL OF CLINICAL PATHOLOGY, vol. 57, no. 11, 25 November 2009 (2009-11-25), pages 1066 - 1074 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021025791A (ja) * | 2019-07-31 | 2021-02-22 | アークレイ株式会社 | 推定方法及び平均血糖値推定システム |
JP7282298B2 (ja) | 2019-07-31 | 2023-05-29 | アークレイ株式会社 | 推定方法及び平均血糖値推定システム |
Also Published As
Publication number | Publication date |
---|---|
CN107003315A (zh) | 2017-08-01 |
JPWO2016103390A1 (ja) | 2017-06-29 |
JP6401297B2 (ja) | 2018-10-10 |
CN107003315B (zh) | 2018-09-25 |
US20170316176A1 (en) | 2017-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wiley et al. | A metabolic syndrome severity score: A tool to quantify cardio-metabolic risk factors | |
Timar et al. | The impact of diabetic neuropathy on balance and on the risk of falls in patients with type 2 diabetes mellitus: a cross-sectional study | |
Mei et al. | Frailty as a predictor of negative health outcomes in chronic kidney disease: a systematic review and meta-analysis | |
Fritsche et al. | Different effects of lifestyle intervention in high-and low-risk prediabetes: results of the randomized controlled prediabetes lifestyle intervention study (PLIS) | |
Ma et al. | Blood pressure variation and subclinical brain disease | |
JP6870679B2 (ja) | アルツハイマー型認知症の将来の発症リスクの評価方法 | |
Zhang et al. | Comparing the prognostic significance of nutritional screening tools and ESPEN-DCM on 3-month and 12-month outcomes in stroke patients | |
Ruiz-Alejos et al. | Skinfold thickness and the incidence of type 2 diabetes mellitus and hypertension: an analysis of the PERU MIGRANT study | |
Álvarez et al. | Prevalence of non-responders for blood pressure and cardiometabolic risk factors among prehypertensive women after long-term high-intensity interval training | |
Yavuz et al. | Identifying uncontrolled asthma in children with the childhood asthma control test or exhaled nitric oxide measurement | |
Kavsak et al. | High-sensitivity cardiac troponin risk cutoffs for acute cardiac outcomes at emergency department presentation | |
Liff et al. | Cardiorespiratory fitness in patients with rheumatoid arthritis is associated with the patient global assessment but not with objective measurements of disease activity | |
El Moussaoui et al. | Development and validation of a short questionnaire in community acquired pneumonia | |
Lambert et al. | Diagnostic accuracy of FEV1/forced vital capacity ratio z scores in asthmatic patients | |
JP6401297B2 (ja) | インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 | |
Coutts et al. | Psychotic disorders as a framework for precision psychiatry | |
Holdom et al. | Venous creatinine as a biomarker for loss of fat‐free mass and disease progression in patients with amyotrophic lateral sclerosis | |
US20070161868A1 (en) | Method and system for determining whether additional laboratory tests will yield values beyond a threshold level | |
Vianna et al. | Accuracy and adequacy of waist circumference cut-off points currently recommended in Brazilian adults | |
Sushmitha et al. | Exploring the relationship between the indices of body composition with grip strength performance and peak VO2 | |
JP5811545B2 (ja) | 疲労のバイオマーカーおよびその利用 | |
Barbosa-Leiker et al. | Longitudinal measurement invariance of the metabolic syndrome: is the assessment of the metabolic syndrome stable over time? | |
Delaney et al. | Pitfalls in the measurement of the nocturnal blood pressure dip in adolescents with type 1 diabetes | |
Muñoz-Hernando et al. | Diagnosis accuracy of waist-to-height ratio to predict cardiometabolic risk in children with obesity | |
Fuentes-Abolafio et al. | Kinematic parameters related to functional capacity, fatigue, and breathlessness during the 6-min walk test in older adults with heart failure with preserved ejection fraction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14908997 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016565750 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15517642 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14908997 Country of ref document: EP Kind code of ref document: A1 |